Netscientific Share Discussion Threads

[blakieboy7] 15/8/2023 20:08

PDSB now over 13% up, over 6 dollars now

[blakieboy7] 15/8/2023 18:54

Agreed Loaf, it's madness

[loafofbread] 15/8/2023 18:44

I do think that PDSB will hit the $1B valuation, $25+, if the readouts continue to impress.

It is not just one drug but the whole platform that will come through.

That will add £20M+ to our valuation and take us over £2.00.

Add in the rest of the investments and 60p is just crazy. If Glycotest comes in you are looking at £3, £4 or £5 a share.



So far I have from the latest results and recent RNS.


Vortex £3M
SageTech £1M
QBot. £3M+
PDSB. £6.5M (@ $6.00)
DNAME. £1M
Cytrovale £1M
EMV. £5M (Premiums being paid everywhere for fund /asset managers)
Cash. £1M

Total £21.5M vs MCap of £14M

The ones above have real world values and are worth more than our Market Cap.

Glycotest is valued at another £11M in the books. Sale/fund raise before end of year.

Proaxis is valued at another £3M + in the books. Sale/fund raise before end of year.

Plus another 25 investments.

Insane value.

[blakieboy7] 15/8/2023 16:05

PDSB up yet another 8% so far

[loafofbread] 15/8/2023 08:24

At some point the market will wake up to this.

[blakieboy7] 15/8/2023 07:58

Loaf, Q4 should be really interesting for PDSB

[loafofbread] 14/8/2023 23:18

Excellent news just keeps coming from PDSB.

Quite why NSCI puts out the RNS at 6pm is beyond me.

Blackrock keep adding and now have 5%+ of PDSB.

Pretty sure todays 10% is just the start.

[blakieboy7] 10/8/2023 14:56

Latest PDSB video from Frank hTtps://youtu.be/tf8FGxVJ3SI

[kingston78] 08/8/2023 08:39

Q-Bot has a great future as a business.

[loafofbread] 03/8/2023 21:33

So far I have from the latest results and recent RNS.


Vortex £3M
SageTech £1M
QBot. £3M+
PDSB. £6.5M (@ $6.00)
DNAME. £1M
Cytrovale £1M
EMV. £5M (Premiums being paid everywhere for fund /asset managers)
Cash. £1M

Total £21.5M vs MCap of £14M

The ones above have real world values and are worth more than our Market Cap.

Glycotest is valued at another £11M in the books. Sale/fund raise before end of year.

Proaxis is valued at another £3M + in the books. Sale/fund raise before end of year.

Plus another 25 investments.

Insane value.

[blakieboy7] 03/8/2023 16:28

PDSB up over 5% so far today

[kingston78] 02/8/2023 12:39

Energy saving and heat insulation are big businesses, however, most people could not afford an expensive heat pump, nor are there sufficient number of qualified heat engineers to install them, so the take up of heat pumps is relatively slow and it will not hit the government targets by 2028.

This turns my attention to Q-BOT, which is 100% owned by NSCI. I see this subsidiary having a long term sustainable and profitable business. Given time, say three years of demonstrable trading record it could be worth potentially more than £10 million to NSCI Group. Illustratively, say it makes a pre-tax profit of £1 million with a projected £10 million annual turnover, take away 25% tax, giving it a post tax profit of £750,000. At a P/E of 13 will value it at £9,750,000.

[loafofbread] 01/8/2023 22:24

Cytovale® Announces Commercial Launch of IntelliSep® Sepsis Test, the First-of-its-Kind Diagnostic Tool for Emergency Departments
Our Lady of the Lake Regional Medical Center in Baton Rouge, Louisiana, is the first to deploy IntelliSep to support early detection of sepsis in at-risk patients

Sepsis is a leading driver of death and hospitalization costs in the United States

August 01, 2023 09:00 AM Eastern Daylight Time
SAN FRANCISCO--(BUSINESS WIRE)--Cytovale®, a pioneering medical diagnostics company focused on advancing early detection technologies to diagnose fast-moving and immune-mediated diseases, announced today the U.S. commercial launch of the IntelliSep® sepsis test following FDA 510(k) clearance in December 2022. Our Lady of the Lake Regional Medical Center in Baton Rouge, Louisiana, is the first U.S. medical center to adopt IntelliSep for emergency department (ED) use. The test aids in the rapid diagnosis of sepsis for adult patients with signs and symptoms of infection, providing results in under 10 minutes.

"Sepsis is one of the most common conditions impacting emergency departments in the United States, and there has not been a timely test to identify sepsis early until now,” said Hollis O’Neal, MD, Medical Director of Research at Our Lady of the Lake Regional Medical Center and Critical Care Physician at LSU Health Sciences Center. “With the IntelliSep test, we can deliver the right care to the right patients at the right time and we are excited to be the first hospital in the country to implement this technology. I’m really excited for what the future brings.”

The IntelliSep test is a groundbreaking diagnostic tool that categorizes patients into three bands according to their probability of sepsis based on a standard blood draw. The results may equip providers with a tool to optimize clinical outcomes and empower hospitals to improve resource utilization and achieve operational excellence. IntelliSep may also support hospital efforts to meet guidelines set by the Centers for Medicare & Medicaid Services (CMS) for timely sepsis treatment, known as SEP-1.

Sepsis is the leading cause of death worldwide and is responsible for more than 350,000 deaths every year in the United States alone—more than opioid overdoses, prostate cancer, and breast cancer combined.1,2 Quickly recognizing sepsis is critical to saving lives because the risk of death can increase by as much as eight percent each hour the condition is undiagnosed and untreated. As many as 80 percent of these deaths could be prevented with rapid diagnosis and treatment – making early detection critical to improving clinical, operational, and financial outcomes.1

“The launch of the IntelliSep test is a huge moment in our fight against the devastating impact of sepsis,” said Cytovale co-founder and CEO Ajay Shah. “We know early detection and diagnosis is key, and we’re proud to have a partner in Our Lady of the Lake and look forward to seeing IntelliSep’s impact at other Franciscan Missionaries of Our Lady Health System (FMOLHS) hospitals.”

Our Lady of the Lake Health is part of FMOLHS, which includes 10 hospitals across Louisiana and Mississippi. Cytovale is working to launch IntelliSep across the broader FMOLHS network and an expanded clinical network through the health system’s partnership with Louisiana State University. The company is also in discussions with additional hospital systems across the U.S. so that the impact of IntelliSep on early sepsis identification and patient risk stratification may be extended to additional emergency departments seeking such a solution.

[blakieboy7] 01/8/2023 08:44

Interesting interview with Frank B - htTps://www.benzinga.com/general/biotech/23/07/33373627/pds-biotechnology-top-line-data-from-its-lead-candidate-points-to-promising-future-for-this-compa

[loafofbread] 31/7/2023 23:26

Another 5% since our close.

[blakieboy7] 31/7/2023 08:11

Blue start on a Monday!

[blakieboy7] 29/7/2023 15:25

Great to see PDSB recoverer on Friday. More news due from them in October, not long to wait

[blakieboy7] 29/7/2023 15:07

Loaf, I voted up your post on LSE under your Biffa avatar

[kingston78] 29/7/2023 14:20

The share price of PDSB is US$5.43 with a price target of US$18. PDSB has fallen so much but brokers' consensus remains positive. That speaks volume for the attraction of NSCI.

[loafofbread] 29/7/2023 11:21

Some half decent buying of NSCI followed by a straight 10% rise of PDSB stock on no news!

Roll on Monday.

[loafofbread] 28/7/2023 13:15

Yup.

Someone has woken up.

Hopefully the tea lady has had a sniff of something.

[blakieboy7] 28/7/2023 13:12

That's a bit better

[loafofbread] 26/7/2023 13:53

Lots of old dogs having a bit of a run at the moment.

OPTI 6p to 42p. A massive red stain on my IG account that has finally gone.

Can't see any reason why we won't get a bit of the action with our 30+ investments all looking a little bit better every week.